ProCE Banner Activity

OV21/PETROC: IP vs IV Chemo After Neoadjuvant Chemo and Optimal Cytoreduction in Epithelial Ovarian Cancer

Slideset Download
Conference Coverage
IP carboplatin shows substantial reduction in PD rates at 9 months vs IV chemotherapy with similar tolerability.

Released: June 09, 2016

Expiration: June 08, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals